Intercept Pharmaceuticals’ Post

Over several years, Cecilia was bounced from doctor to doctor until she found someone who finally listened to her concerns and properly diagnosed her with primary biliary cholangitis (#PBC). Ensuring patient voices are heard and understood is a critical aspect of healthcare, and especially important when diagnosing and managing #rarediseases. Watch Cecilia recount her experience with PBC.

It was great to connect in person with the global liver health community at this year’s #EASLCongress in Milan! Thank you to everyone who met with us.

Join us in wishing the Global Liver Institute a very happy 10th anniversary! We had a great time celebrating the past decade in Milan, and we can’t wait to see what the future may bring.  

We’re pleased to announce late breaking data at #EASLCongress from our Phase 2 combination study in primary biliary cholangitis (#PBC). Learn more: https://lnkd.in/eVqQ-ypf

We’re proud to support the American Liver Foundation’s Liver Life Walk. Our team had a great time in NJ walking alongside the community!

We’re looking forward to engaging with the #liver community at #EASLCongress 2024 in Milan, where we’re presenting our latest research in #PBC. We hope to see you there! 

Will you be at #EASLCongress 2024? Learn more about data being shared from our landmark Phase 3 POISE study in primary biliary cholangitis (#PBC): https://lnkd.in/eHKPV-RN

We’re excited to announce the acceptance of multiple abstracts at #EASLCongress 2024, including 7 posters on #PBC. Learn more: https://lnkd.in/eKk3TCnm

Today we celebrate the 8th anniversary of the approval of our medicine for primary biliary cholangitis (PBC). As we reflect on this remarkable journey of nearly a decade, we are grateful for the opportunity to support those living with #PBC, whose strength and resilience inspire us every day.